2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Chatham W, Clark K, Furie R, Groark J, Urowitz M, van Vollenhoven R, Daniels M, Fox N, Gregan Y, Henderson R, van Maurik A, Ocran-Appiah J, Oldham M, Roth D, Shanahan D, Tak P, Teng Y. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals Of The Rheumatic Diseases 2024, 83: ard-2024-225686. PMID: 39159997, PMCID: PMC11503042, DOI: 10.1136/ard-2024-225686.Peer-Reviewed Original ResearchSystemic lupus erythematosusProportion of patientsCycles of rituximabSubcutaneous belimumabLupus erythematosusSafety of sequential therapyModified intention-to-treat populationIntention-to-treat populationDisease control durationDisease controlInvestigation of combination treatmentsDisease activity markersAnti-dsDNA antibodiesDisease activity controlIntravenous placeboImmunosuppression withdrawalIntravenous rituximabSequential therapyClinical remissionStandard therapySecondary endpointsActivation markersAnti-dsDNARituximabPhase 3
2013
OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations
Schmitt C, Roth D, Birch H, Kleoudis C, De Vries J. OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations. Annals Of The Rheumatic Diseases 2013, 72: a90. DOI: 10.1136/annrheumdis-2013-eular.320.Peer-Reviewed Original ResearchSF-36 physical component scoreEfficacy of belimumabPhysician global assessmentHigh disease activityPhysical component scoreSLE patientsSELENA-SLEDAIDisease activityMean physician’s global assessmentSystemic lupus erythematosus patientsSF-36Treating SLE patientsDisease activity groupLupus erythematosus patientsSLE Responder IndexWeeks of treatmentDisease activity criteriaBelimumab doseFACIT-Fatigue scoresLow complementDouble-blindPlus standard carePrimary endpointSecondary endpointsDisease flare